Abstract : In the search for effective , selective , and nontoxic antiviral and antitumor agents , a variety of strategies have been devisedto designnucleoside analogues
ResearchersdesignedPGF2a analogues
to test the importance of the side - chain features of tryptophan by using a recently developed method for stereoselective fragment religation in yeast cytochrome c. Thermal stability of apolipoprotein A(passive) were designedSemisynthetic analogues
for potent androgen receptor ( AR ) antagonists through rational drug design(passive) was discoveredenzalutamide analogues
by modifying the original chemical structure of a compound — for example , by adding a hydroxyl group(passive) are createdAnalogues
modifying the original chemical structure of a compound to evade detection by the FDA , making the products more difficult to regulate , and to reduce the risk of patent - infringement lawsuits(passive) are created byAnalogues
the thyronine structure ... upon whichto designanalogues
Baldinger Vu - Huu ( winner ) – Episodic Urbanism , by Peter Elliott and contributors , published by Uro Publications , designed by Stuart Geddes – Nicholas Mangan : Limits to Growth , published by Monash University Museum of Art and Sternberg Press , Berlin(passive) designed byAnalogues
to catalyze asymmetric reactions via enamine intermediates with the assistance of tunable hydrogen bonding(passive) have been designedProlinamide analogues
modelled and synthesised which incorporated alternative ' LHS ' fragments linked via either an amide or urea to a privileged ' RHS ' fragment commonly found in CGRP receptor antagonists(passive) were designedAnalogues
to mimic naturally occuring nucleotides(passive) are synthetically createdNucleoside analogues
likelyto causedephosphorylation of monophosphorylated nucleoside analogues
CellMed(passive) discovered byGLP-1 analogues
acid dietary different analogous food readily resistanceledanalogues
to be incorporated into viral nucleic acids and act as chain terminators thus inhibiting efficient viral replication(passive) are designedNucleoside analogues
that are inherently straightforward to synthesise(passive) will be designedAnalogues
synthesizedand characterized.screened for their in - vivo analgesic , anti - pyretic and DNA cleavagestudies(passive) were designedanalogues
as the high affinity niacin receptor G - protein - coupled receptor 109A(passive) were rationally designedTricyclic analogues
using a conformation - based strategy on active core regions(passive) were designedNeuropeptide analogues
Pharmacistshave createdRiboxin analogues
modifying various structural elements of natural nucleic acids(passive) may be created byAnalogues
et lescomposespolycycliques analogues
to closely resemble the naturally occurring nucleoside adenine , one of the essential building blocks of RNA , which carries the virus ’ genetic information(passive) are designedNucleoside analogues
modelled and synthesized(passive) were designedAnalogues
to modulate the binding affinity toward G - actin(passive) were designedAnalogues
based on a lead compound that was previously determined to have selective activity as a GPR35 antagonist(passive) were designedAnalogues
replacing the central histidine with substituted pyridinium moieties(passive) were designed byTRH ) analogues
In taking any modern any type of class , course will finddiscoveranalogues
to be potent and selective for p38 , with an emphasis on slow enzyme dissociation kinetics to deliver prolonged lung p38 inhibition(passive) have been designedAnalogues
as derivatives of eitherthe biaryl(passive) were designedAnalogues
the loss or depletion of nucleoside kinases(passive) caused bynucleoside analogues
of n = 5 - 15 phenol subunits [ 56(passive) are composedanalogues
modeling was usedto designanalogues
adding methyl groups in the ester side chain elongating the length to form ethyl , isopropyl , sec - butyl and neo - pentyl acetates(passive) were created byAnalogues
Side Chains / TerminalsCreatingAnalogues
taking Imatinib as a prototype(passive) have been designed byAnalogues
GT110507to leadtacrolimus analogues
to investigate the effects of modification of these factors on antimicrobial activities ( Table1(passive) were designedAnalogues
to treat hepatitis C virus ( HCV ) infections and potentially other diseasesdesignedto treat hepatitis C virus ( HCV ) infections and potentially other diseases
for selective inhibition of GAR Tfase versus thymidylate synthase or dihydrofolate reductase Bioorganic and Medicinal Chemistrydesignedfor selective inhibition of GAR Tfase versus thymidylate synthase or dihydrofolate reductase Bioorganic and Medicinal Chemistry
mitochondrial toxicity to varying degreesmay causemitochondrial toxicity to varying degrees
to combine the most favorable pharmacokinetic properties of fludarabine and cladribinedesignedto combine the most favorable pharmacokinetic properties of fludarabine and cladribine
the hormonal - induced activation of nuclear receptors such as MR and also GR by inducing their degradation via the ubiquitin - proteasome system [ 6 ] , [ 7 ] , [ 8preventthe hormonal - induced activation of nuclear receptors such as MR and also GR by inducing their degradation via the ubiquitin - proteasome system [ 6 ] , [ 7 ] , [ 8
to full restoration of the barrier function of the skinare contributingto full restoration of the barrier function of the skin
using both acyclic and cyclic templatesdesignedusing both acyclic and cyclic templates
using both acyclic and cyclic ovenightdesignedusing both acyclic and cyclic ovenight
to support drug discovery and development researchdesignedto support drug discovery and development research
to treat hepatitis C virus ( HCV ) infections , licensed to Boehringer Ingelheim , and a series of candidate drugs aimed at treatment of respiratory syncytial virus ( RSV ) diseasedesignedto treat hepatitis C virus ( HCV ) infections , licensed to Boehringer Ingelheim , and a series of candidate drugs aimed at treatment of respiratory syncytial virus ( RSV ) disease
for selective inhibition of GAR Tfase versus thymidylate synthase or dihydrofolate reductase 2000 10.1016 / s0968 - 0896(00)00051 - 1 10882019 http://vivo.scripps.edu/individual/endnote193708designedfor selective inhibition of GAR Tfase versus thymidylate synthase or dihydrofolate reductase 2000 10.1016 / s0968 - 0896(00)00051 - 1 10882019 http://vivo.scripps.edu/individual/endnote193708
more weight loss ( Table ) and gastrointestinal side effects than controls ( nausea , relative risk increase [ RRI ] 192 % , 95 % CI 102 to 324 ; vomiting , RRI 232 % , CI 151 to 341 ; and diarrhea , RRI 123 % , CI 72 to 189causedmore weight loss ( Table ) and gastrointestinal side effects than controls ( nausea , relative risk increase [ RRI ] 192 % , 95 % CI 102 to 324 ; vomiting , RRI 232 % , CI 151 to 341 ; and diarrhea , RRI 123 % , CI 72 to 189
neuropathy exert direct mitochondrial toxicity that is not mediated indirectly through the inhibition of DNA polymerase - γcauseneuropathy exert direct mitochondrial toxicity that is not mediated indirectly through the inhibition of DNA polymerase - γ
liver injury by several mechanismscan causeliver injury by several mechanisms
to 9-deazaxanthine derivatives as dual A(2A ) antagonists / MAO - B inhibitorsleadingto 9-deazaxanthine derivatives as dual A(2A ) antagonists / MAO - B inhibitors
the immune outcome of glycolipid administration ... particularly to improve the clinical efficacy of CD1d - binding glycolipidsinfluencethe immune outcome of glycolipid administration ... particularly to improve the clinical efficacy of CD1d - binding glycolipids
from substitution of amino acids with similar chemical characteristics to the originalresultingfrom substitution of amino acids with similar chemical characteristics to the original
and synthesized based on structure - activity relationships and molecular modeling ... 18 , 21 , 22 , 26 , 31 , 34have been designedand synthesized based on structure - activity relationships and molecular modeling ... 18 , 21 , 22 , 26 , 31 , 34
a testosterone spike in the first few weeks of usagetriggera testosterone spike in the first few weeks of usage
less adrenocortical suppression ETOMIDATE is a potent and rapidly acting imidazole - based anesthetic agent that is highly valued for its minimal effects on breathing and blood pressure andcauseless adrenocortical suppression ETOMIDATE is a potent and rapidly acting imidazole - based anesthetic agent that is highly valued for its minimal effects on breathing and blood pressure and
decades ago but never put into legitimate usediscovereddecades ago but never put into legitimate use
a small increase in cell deaths in the first minutes of each experiment , followed by relative sparing from further neurodegenerationcauseda small increase in cell deaths in the first minutes of each experiment , followed by relative sparing from further neurodegeneration
largely on the basis of the crystal structure of the stable “ frozen ” TS analogues or the “ still ” TS structures from the kinetic studiesare designedlargely on the basis of the crystal structure of the stable “ frozen ” TS analogues or the “ still ” TS structures from the kinetic studies
dollars of life coming online structure ... a size between quantum and right , and the Press of composite strategies of another without polychronic members ... although not identifies the spacetime in examples not seek philosophical relationships in these physicists within this welfare Koski and Sterck , 2009contributedollars of life coming online structure ... a size between quantum and right , and the Press of composite strategies of another without polychronic members ... although not identifies the spacetime in examples not seek philosophical relationships in these physicists within this welfare Koski and Sterck , 2009
as metabolically stable surrogates of the natural nucleosidesdesignedas metabolically stable surrogates of the natural nucleosides
to more closely mimic Raloxifenedesignedto more closely mimic Raloxifene
to overcome AAC(6′)s and strategies for blocking AAC(6′)sdesignedto overcome AAC(6′)s and strategies for blocking AAC(6′)s
of alternative backbone structures containing internucleotide linkages such as methylphosphonate , phosphotriester , phosphorothioate , peptide , and the likecomposedof alternative backbone structures containing internucleotide linkages such as methylphosphonate , phosphotriester , phosphorothioate , peptide , and the like
from supplementation of AHBA analogueresultingfrom supplementation of AHBA analogue
mitochondrial perform to your variable diploma , which can be most pronounced with stavudine , didanosine and zidovudinemay influencemitochondrial perform to your variable diploma , which can be most pronounced with stavudine , didanosine and zidovudine
to act as inhibitory competitors of viral polymerasesdesignedto act as inhibitory competitors of viral polymerases
to mimic both the methyl donor S - adenosylmethionine ( AdoMetdesignedto mimic both the methyl donor S - adenosylmethionine ( AdoMet
sometimescan ... causesometimes
to act as competitive alternative substrate inhibitors of virally encoded polymerasesdesignedto act as competitive alternative substrate inhibitors of virally encoded polymerases
Akt translocation , 389IL-4 cytotoxin , xenograft models , 245 in vivopreventAkt translocation , 389IL-4 cytotoxin , xenograft models , 245 in vivo
to mimic the structures of the natural building blocks of DNA and RNAdesignedto mimic the structures of the natural building blocks of DNA and RNA
recurrence of hepatitis B virus ( HBV ) infectioncan preventrecurrence of hepatitis B virus ( HBV ) infection
Akt translocation , 389novel xenograft model for human FAP expression , 729PXD101 , a novel HDAC inhibitor , 721role of PKC δ , 273Trx-1 inhibitors PX-12 and pleurotin , 235MCF7preventAkt translocation , 389novel xenograft model for human FAP expression , 729PXD101 , a novel HDAC inhibitor , 721role of PKC δ , 273Trx-1 inhibitors PX-12 and pleurotin , 235MCF7
and synthesized and tested for their anti - epileptic activitywere designedand synthesized and tested for their anti - epileptic activity
above with known affinity for the regulator proteindesignedabove with known affinity for the regulator protein